Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

At the heart of this issue is the protein rhodopsin, which, due to genetic mutations, often misfolds. This misfolding disrupts its function, leading to retinal cell degeneration. Scientists have ...

Very little is known about the molecular structures of retinal antigens. One possibility is that an immune response may result from a defect in maintaining tolerance for self-antigens, e. g., ...

Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

In retinitis pigmentosa the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

Light is a powerful source of energy that is used for various biological purposes. Some organisms harness light to produce ATP, the energy currency of cells, while others use light to interpret ...

Treatment with bioavailable small-molecule pharmacochaperones targeting the visual receptor rhodopsin offers a promising approach to prevent retinal photoreceptor degeneration caused by inherited ...